Trevena (NASDAQ: TRVN) recently received a number of ratings updates from brokerages and research firms:

  • 10/18/2017 – Trevena was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.50 price target on the stock. According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
  • 10/16/2017 – Trevena was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $2.50 price target on the stock, down previously from $15.00.
  • 10/12/2017 – Trevena had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a “buy” rating on the stock.
  • 10/12/2017 – Trevena was given a new $5.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/25/2017 – Trevena was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “

Trevena, Inc. (TRVN) opened at 1.60 on Tuesday. The firm’s market capitalization is $95.51 million. The stock’s 50 day moving average price is $2.37 and its 200-day moving average price is $2.65. Trevena, Inc. has a one year low of $1.57 and a one year high of $8.00.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). On average, equities research analysts anticipate that Trevena, Inc. will post ($1.36) earnings per share for the current fiscal year.

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.